Tumor Biology

, Volume 37, Issue 1, pp 419–424 | Cite as

CCR7 regulates Twist to induce the epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma

  • Kexin Li
  • Baofeng Xu
  • Guangying Xu
  • Rui LiuEmail author
Original Article


As reported, the CC chemokine receptor 7 (CCR7) trigger a series of signaling cascades in the epithelial-mesenchymal transition (EMT) of some malignancies. Meanwhile, Twist promotes EMT in pancreatic ductal adenocarcinoma (PDAC) progression. Here, effects of Twist on CCR7-induced EMT in the PDAC were investigated in detail. The immunohistochemistry was used to detect the expression of Twist, and then, in vitro assays were applied. The expression rate of Twist was 72.0 % in PDAC samples and closely correlated with tumor-node-metastasis (TNM) stage and invasion. When PDAC cell line PANC1 was subjected to CCL19 stimulation, the expression of p-ERK, p-AKT, Twist, N-cadherin, MMP9, and α-smooth muscle actin (α-SMA) was induced, while the GSK1120212, BEZ235, and MK2206 prohibited the increase of Twist and EMT biomarkers. For another thing, the si-Twist treatment attenuated CCL19-stimulated EMT occurrence, migration, and invasion phenotypes of PANC1 cells. In conclusion, CCR7 pathway up-regulates Twist expression via ERK and PI3K/AKT signaling to manage the EMT of PDAC. Our work allows for clinical gene or protein-targeted regimen of PDAC patients in the near future.





This study was supported by grants to BFX from Foundation of Jilin Provincial Science & Technology Department [No. 201201044].

Conflicts of interest



  1. 1.
    Song W, Li Q, Wang L, et al. FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Sci Rep. 2015;5:10081.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Aung KL, Moore MJ. Metformin for pancreatic cancer. Lancet Oncol. 2015.Google Scholar
  3. 3.
    Blanco VM, Latif T, et al. Imaging and therapy of pancreatic cancer with phosphatidylserine-targeted nanovesicles. Transl Oncol. 2015;8:196–203.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Helm O, Mennrich R, Petrick D, et al. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. PLoS One. 2014;9(5):e94357.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chee CE, Krishnamurthi S, Nock CJ, et al. Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist. 2013;18(10):1091–2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Distler M, Kersting S, Niedergethmann M, et al. Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg. 2013;258(2):324–30.CrossRefPubMedGoogle Scholar
  7. 7.
    Laghi L, Beghelli S, Spinelli A, et al. Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One. 2012;7(9):e46002.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Comerford I, Harata-Lee Y, Bunting MD, et al. A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev. 2013;24(3):269–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Chang WJ, Du Y, Zhao X, et al. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 2014;20(16):4586–96.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16:488–94.CrossRefPubMedGoogle Scholar
  11. 11.
    Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014;35:7335–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Guo J, Lou W, Ji Y, Zhang S. Effect of CCR7, CXCR4 and VEGF-C on the lymph node metastasis of human pancreatic ductal adenocarcinoma. Oncol Lett. 2013;5(5):1572–8.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Polvani S, Tarocchi M, Tempesti S, et al. Nuclear receptors and pathogenesis of pancreatic cancer. World J Gastroenterol. 2014;20(34):12062–81.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hausmann S, Kong B, Michalski C, et al. The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 2014;816:129–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee WT, Lee TH, Cheng CH, et al. Antroquinonol from antrodia camphorata suppresses breast tumor migration/invasion through inhibiting ERK-AP-1- and AKT-NF-κB-dependent MMP-9 and epithelial-mesenchymal transition expressions. Food Chem Toxicol. 2015.Google Scholar
  17. 17.
    Qu BL, Yu W, Huang YR, et al. 6-OH-BDE-47 promotes human lung cancer cells epithelial mesenchymal transition via the AKT/Snail signal pathway. Environ Toxicol Pharmacol. 2014;39:271–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Jung HY, Yang J. Unraveling the TWIST between EMT and cancer stemness. Cell Stem Cell. 2015;16:1–2.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of EndocrinologyPeople’s Hospital of Jilin ProvinceChangchunChina
  2. 2.Department of NeurosurgeryFirst Hospital of Jilin UniversityChangchunChina
  3. 3.Changchun Emergency CenterChangchunChina
  4. 4.Department of EndocrinologyChina-Japan Union Hospital of Jilin UniversityChangchunChina

Personalised recommendations